Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytokinetics (NQ: CYTK )

44.84 -0.17 (-0.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 649,443
Open 45.00
Bid (Size) 44.50 (1)
Ask (Size) 47.00 (10)
Prev. Close 45.01
Today's Range 44.62 - 45.63
52wk Range 30.27 - 55.80
Shares Outstanding 94,631,001
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga

Performance

YTD
+1.10%
+1.10%
1 Month
+6.00%
+6.00%
3 Month
+22.82%
+22.82%
6 Month
-16.25%
-16.25%
1 Year
+28.30%
+28.30%

More News

Read More
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
Via Benzinga
Analyst Ratings for Cytokinetics
Via Benzinga
Expert Ratings for Cytokinetics
Via Benzinga
What 7 Analyst Ratings Have To Say About Cytokinetics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
Via Benzinga
Cytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Said
Via Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
Via Benzinga
FDA Adcomm Gives Thumbs Down To Cytokinetics' Heart Failure Candidate
Via Benzinga
Where Cytokinetics Stands With Analysts
Via Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug
Via Investor's Business Daily
Top Stories Today: Jack Dorsey Not Exactly Impressed With Elon Musk's Twitter; Binance Sees $3B Outflow In 7 Days..
Via Benzinga
Analyst Ratings for Cytokinetics
Via Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Via Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
Via Investor's Business Daily
Coca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306%
Via Benzinga
Swing Trading Stock Watchlist For The Week Of Sept. 6
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Via Benzinga
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Via Benzinga
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
Via Benzinga
What 5 Analyst Ratings Have To Say About Cytokinetics
Via Benzinga
Cytokinetics Records $89M Q2 Sales On Deferred Mavacamten Revenues, Forecasts FY22 Cash Of Over $800M
Via Benzinga
Recap: Cytokinetics Q2 Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.